In order to solve the problems of overcrowding of the same variety of transdermal preparation track, long project approval cycle, inaccurate judgment, mostly relying on imports of key accessories and key equipment, and lack of in-depth research on the whole life cycle of products, Pharmax (Beijing) Co., Ltd. jointly with China Transdermal Technology Alliance, invited a number of senior practitioners and industry investors in the industry. In-depth exchanges on the industry development, opportunities and challenges, registration regulations, improved new drugs, marketing and other topics in the field of transdermal preparations, to help enterprises avoid pitfalls in the field of transdermal preparations, anticipate the future competitive environment, rationally accelerate research and development progress, advance docking sales resources, and obtain more cutting-edge business opportunities.
China Pharmaceutical Conference on Controlled Release, Targeted agents and Improved New drugs
With the support of the policy, China's new slow-release preparation industry such as microsphere slow-release preparation has been greatly developed, the progress of slow-release technology, low cost, short cycle, high patient compliance, good drug stability and other significant advantages, to create better health for patients, bring greater commercial value for enterprises, so that the slow-release preparation has attracted the attention of the industry. It has become an important direction and investment hotspot of domestic drug research and development. With the support of the China Chemical and Pharmaceutical Industry Association, the Pharmaceutical Industry has jointly built a co-construction and sharing exchange platform for Chinese pharmaceutical industry colleagues to discuss the problems encountered in the process of slow and controlled release technology, targeted preparation technology and dosage form improvement, mutual understanding, mutual cooperation, co-construction and sharing.
